A detailed history of Advantage Alpha Capital Partners LP transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 46,151 shares of DVAX stock, worth $599,963. This represents 0.12% of its overall portfolio holdings.

Number of Shares
46,151
Previous 80,250 42.49%
Holding current value
$599,963
Previous $901,000 42.95%
% of portfolio
0.12%
Previous 0.2%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$10.05 - $11.61 $342,694 - $395,889
-34,099 Reduced 42.49%
46,151 $514,000
Q2 2024

Aug 13, 2024

SELL
$10.73 - $12.58 $90,486 - $106,087
-8,433 Reduced 9.51%
80,250 $901,000
Q1 2024

May 13, 2024

SELL
$11.7 - $14.98 $4,726 - $6,051
-404 Reduced 0.45%
88,683 $1.1 Million
Q4 2023

Feb 13, 2024

BUY
$13.09 - $14.98 $1.17 Million - $1.33 Million
89,087 New
89,087 $1.25 Million

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.64B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Advantage Alpha Capital Partners LP Portfolio

Follow Advantage Alpha Capital Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advantage Alpha Capital Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Advantage Alpha Capital Partners LP with notifications on news.